Asset Details
Do you wish to reserve the book?
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine
Do you wish to request the book?
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine
2011
Overview
Towards T-cell vaccines for HIV/AIDS
Following some high-profile clinical trial failures in recent years, the emphasis in HIV/AIDS vaccine research has shifted away from T-cell-based vaccines that control viral replication towards vaccines that block acquisition of infection. Hansen
et al
. take a novel route to T-cell-based immunity, using cytomegalovirus (CMV) vectors. They find that vaccination with a rhesus-CMV-based vaccine against simian immunodeficiency virus (SIV) provides long-term protection from SIV challenge in rhesus macaques. Protection seems to be mediated by tissue-resident T-effector memory responses, suggesting that persistent vectors such as CMV may be effective in HIV/AIDS vaccines.
The acquired immunodeficiency syndrome (AIDS)-causing lentiviruses human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) effectively evade host immunity and, once established, infections with these viruses are only rarely controlled by immunological mechanisms
1
,
2
,
3
. However, the initial establishment of infection in the first few days after mucosal exposure, before viral dissemination and massive replication, may be more vulnerable to immune control
4
. Here we report that SIV vaccines that include rhesus cytomegalovirus (RhCMV) vectors
5
establish indefinitely persistent, high-frequency, SIV-specific effector memory T-cell (T
EM
) responses at potential sites of SIV replication in rhesus macaques and stringently control highly pathogenic SIV
MAC239
infection early after mucosal challenge. Thirteen of twenty-four rhesus macaques receiving either RhCMV vectors alone or RhCMV vectors followed by adenovirus 5 (Ad5) vectors (versus 0 of 9 DNA/Ad5-vaccinated rhesus macaques) manifested early complete control of SIV (undetectable plasma virus), and in twelve of these thirteen animals we observed long-term (≥1 year) protection. This was characterized by: occasional blips of plasma viraemia that ultimately waned; predominantly undetectable cell-associated viral load in blood and lymph node mononuclear cells; no depletion of effector-site CD4
+
memory T cells; no induction or boosting of SIV Env-specific antibodies; and induction and then loss of T-cell responses to an SIV protein (Vif) not included in the RhCMV vectors. Protection correlated with the magnitude of the peak SIV-specific CD8
+
T-cell responses in the vaccine phase, and occurred without anamnestic T-cell responses. Remarkably, long-term RhCMV vector-associated SIV control was insensitive to either CD8
+
or CD4
+
lymphocyte depletion and, at necropsy, cell-associated SIV was only occasionally measurable at the limit of detection with ultrasensitive assays, observations that indicate the possibility of eventual viral clearance. Thus, persistent vectors such as CMV and their associated T
EM
responses might significantly contribute to an efficacious HIV/AIDS vaccine.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Acquired immune deficiency syndrome
/ AIDS
/ Animals
/ CD4-Positive T-Lymphocytes - immunology
/ CD8-Positive T-Lymphocytes - immunology
/ Control
/ DNA
/ HIV
/ Human immunodeficiency virus
/ Humanities and Social Sciences
/ Immunity, Mucosal - immunology
/ Immunologic Memory - immunology
/ letter
/ Male
/ Methods
/ Plasma
/ Science
/ Simian Acquired Immunodeficiency Syndrome - blood
/ Simian Acquired Immunodeficiency Syndrome - immunology
/ Simian Acquired Immunodeficiency Syndrome - prevention & control
/ Simian Acquired Immunodeficiency Syndrome - virology
/ Simian immunodeficiency virus
/ Simian Immunodeficiency Virus - growth & development
/ Simian Immunodeficiency Virus - immunology
/ Simian Immunodeficiency Virus - isolation & purification
/ Simian Immunodeficiency Virus - pathogenicity
/ T cells
/ Vaccines
